Literature DB >> 16265260

Technology insight: targeting of biological molecules for evaluation of high-risk atherosclerotic plaques with magnetic resonance imaging.

Michael J Lipinski1, Valentin Fuster, Edward A Fisher, Zahi A Fayad.   

Abstract

Identification of high-risk atherosclerotic lesions prone to rupture and thrombosis may greatly decrease the morbidity and mortality associated with atherosclerosis. The development of magnetic resonance imaging contrast agents that specifically target components of the atherosclerotic plaque might enable non-invasive detection of high-risk lesions. This review discusses a variety of molecules present in atherosclerotic plaque that could serve as targets for specific contrast agents. Ultimately, such agents may allow the identification of high-risk atherosclerotic lesions in patients and enable treatment of these patients before lesion progression and complications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16265260     DOI: 10.1038/ncpcardio0013

Source DB:  PubMed          Journal:  Nat Clin Pract Cardiovasc Med        ISSN: 1743-4297


  13 in total

1.  Identification of interleukin-2 for imaging atherosclerotic inflammation.

Authors:  Zahi A Fayad; Vardan Amirbekian; Jean-François Toussaint; Valentin Fuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02       Impact factor: 9.236

Review 2.  Advances in detection and characterization of atherosclerosis using contrast agents targeting the macrophage.

Authors:  Michael J Lipinski; Juan Carlos Frias; Zahi A Fayad
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

Review 3.  Molecular imaging in cardiovascular disease: targets and opportunities.

Authors:  Stanley Y Shaw
Journal:  Nat Rev Cardiol       Date:  2009-07-21       Impact factor: 32.419

Review 4.  Lymphocytes and the adventitial immune response in atherosclerosis.

Authors:  Kirsti A Campbell; Michael J Lipinski; Amanda C Doran; Marcus D Skaflen; Valentin Fuster; Coleen A McNamara
Journal:  Circ Res       Date:  2012-03-16       Impact factor: 17.367

Review 5.  Role and implications of nanodiagnostics in the changing trends of clinical diagnosis.

Authors:  Khalid Khalaf Alharbi; Yazeed A Al-Sheikh
Journal:  Saudi J Biol Sci       Date:  2013-11-19       Impact factor: 4.219

6.  MR molecular imaging of angiogenesis using targeted perfluorocarbon nanoparticles.

Authors:  S D Caruthers; P M Winter; S A Wickline; G M Lanza; J Keupp
Journal:  Medicamundi       Date:  2010

7.  Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis.

Authors:  Michael J Lipinski; Juan C Frias; Vardan Amirbekian; Karen C Briley-Saebo; Venkatesh Mani; Daniel Samber; Antonio Abbate; Juan Gilberto S Aguinaldo; Davis Massey; Valentin Fuster; George W Vetrovec; Zahi A Fayad
Journal:  JACC Cardiovasc Imaging       Date:  2009-05

8.  "Positive contrast" inversion-recovery with ON[corrected]-resonant water suppression magnetic resonance imaging: a change for the better?

Authors:  Michael J Lipinski; Karen C Briley-Saebo; Venkatesh Mani; Zahi A Fayad
Journal:  J Am Coll Cardiol       Date:  2008-08-05       Impact factor: 24.094

Review 9.  Current advances in research and clinical applications of PLGA-based nanotechnology.

Authors:  Jian-Ming Lü; Xinwen Wang; Christian Marin-Muller; Hao Wang; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Expert Rev Mol Diagn       Date:  2009-05       Impact factor: 5.225

10.  Integrating soluble biomarkers and imaging technologies in the identification of vulnerable atherosclerotic patients.

Authors:  José A Páramo; José A Rodríguez Ja; Josune Orbe
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.